v3.26.1
CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY - USD ($)
$ in Thousands
Total
Common Stock
Additional Paid-In Capital
Accumulated Deficit
Accumulated Other Comprehensive Income (Loss)
Balance at beginning of period (in shares) at Dec. 31, 2024   606,388,000      
Balance at beginning of period at Dec. 31, 2024 $ 280,320 $ 606 $ 2,051,794 $ (1,772,341) $ 261
Increase (Decrease) in Stockholders' Equity          
Net loss (19,835)     (19,835)  
Other comprehensive loss 55       55
Foreign currency translation adjustment (12)       (12)
Exercise of pre-funded warrant (in shares)   30,370,000      
Exercise of Pre-Funded Warrant 31 $ 31      
Issuance of common stock under equity plans (in shares)   155,000      
Issuances of common stock under equity plans 256 $ 0 256    
Stock-based compensation related to issuances of common stock and options for services (in shares)   5,000      
Stock-based compensation related to issuances of common stock and options for services 15   15    
Stock-based compensation for equity-based awards to employees and directors 7,408   7,408    
Balance at end of period (in shares) at Mar. 31, 2025   636,918,000      
Balance at end of period at Mar. 31, 2025 268,238 $ 637 2,059,473 (1,792,176) 304
Balance at beginning of period (in shares) at Dec. 31, 2024   606,388,000      
Balance at beginning of period at Dec. 31, 2024 280,320 $ 606 2,051,794 (1,772,341) 261
Increase (Decrease) in Stockholders' Equity          
Net loss (36,210)        
Foreign currency translation adjustment (8)        
Balance at end of period (in shares) at Jun. 30, 2025   637,850,000      
Balance at end of period at Jun. 30, 2025 259,531 $ 638 2,067,327 (1,808,551) 117
Balance at beginning of period (in shares) at Mar. 31, 2025   636,918,000      
Balance at beginning of period at Mar. 31, 2025 268,238 $ 637 2,059,473 (1,792,176) 304
Increase (Decrease) in Stockholders' Equity          
Net loss (16,375)     (16,375)  
Other comprehensive loss (191)       (191)
Foreign currency translation adjustment 4       4
Issuance of common stock under equity plans (in shares)   509,000      
Issuances of common stock under equity plans 591 $ 1 590    
Stock-based compensation related to issuances of common stock and options for services (in shares)   6,000      
Stock-based compensation related to issuances of common stock and options for services 26   26    
Stock-based compensation for equity-based awards to employees and directors 6,738   6,738    
Employee stock purchases (in shares)   417,000      
Employee stock purchases 500   500    
Balance at end of period (in shares) at Jun. 30, 2025   637,850,000      
Balance at end of period at Jun. 30, 2025 259,531 $ 638 2,067,327 (1,808,551) 117
Balance at beginning of period (in shares) at Dec. 31, 2025   639,856      
Balance at beginning of period at Dec. 31, 2025 225,872 $ 640 2,080,804 (1,855,841) 269
Increase (Decrease) in Stockholders' Equity          
Net loss (3,642)     (3,642)  
Other comprehensive loss (412)       (412)
Foreign currency translation adjustment (48)       (48)
Issuance of common stock in connection with exercise of warrants 1,511   1,511    
Issuance of common stock under equity plans (in shares)   1,172      
Issuances of common stock under equity plans 914 $ 1 913    
Stock-based compensation related to issuances of common stock and options for services (in shares)   5      
Stock-based compensation related to issuances of common stock and options for services 13   13    
Stock-based compensation for equity-based awards to employees and directors 4,900   4,900    
Balance at end of period (in shares) at Mar. 31, 2026   641,033      
Balance at end of period at Mar. 31, 2026 229,108 $ 641 2,088,141 (1,859,483) (191)
Balance at beginning of period (in shares) at Dec. 31, 2025   639,856      
Balance at beginning of period at Dec. 31, 2025 225,872 $ 640 2,080,804 (1,855,841) 269
Increase (Decrease) in Stockholders' Equity          
Net loss (20,322)        
Foreign currency translation adjustment (141)        
Balance at end of period (in shares) at Jun. 30, 2026   642,470      
Balance at end of period at Jun. 30, 2026 218,614 $ 642 2,094,474 (1,876,163) (339)
Balance at beginning of period (in shares) at Mar. 31, 2026   641,033      
Balance at beginning of period at Mar. 31, 2026 229,108 $ 641 2,088,141 (1,859,483) (191)
Increase (Decrease) in Stockholders' Equity          
Net loss (16,680)     (16,680)  
Other comprehensive loss (55)       (55)
Foreign currency translation adjustment (93)       (93)
Issuance of common stock under equity plans (in shares)   1,131      
Issuances of common stock under equity plans 1,071 $ 1 1,070    
Stock-based compensation related to issuances of common stock and options for services (in shares)   6      
Stock-based compensation related to issuances of common stock and options for services 16   16    
Stock-based compensation for equity-based awards to employees and directors 4,933   4,933    
Employee stock purchases (in shares)   300      
Employee stock purchases 314   314    
Balance at end of period (in shares) at Jun. 30, 2026   642,470      
Balance at end of period at Jun. 30, 2026 $ 218,614 $ 642 $ 2,094,474 $ (1,876,163) $ (339)